Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Wayrilz (rilzabrutinib) has been ...
Drexel practices a No Harm Test-Optional review for fall entry. This means, with some exceptions, applicants can choose whether to include standardized test scores as part of their application to the ...
Veteran technology journalist of more than 20 years. Former research engineer. Written for more than two dozen publications, including CNET News.com, Dark Reading, MIT's Technology Review, Popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback